EUVIMEDEUVIMED entdecken
Vergleichsstudie

Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab

Andrea Casadei-Gardini, Terry Cheuk-Fung Yip, Alessandro Vitale, Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa und 15 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116750 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Andrea Casadei-Gardini und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, IRCCS San Raffaele Hospital, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy. Electronic address: casadeiga…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Liver Neoplasms, Bevacizumab, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLiver NeoplasmsBevacizumabCarcinoma, HepatocellularAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalImmunotherapyHumansMaleFemaleMiddle AgedTime Factors

Stichwörter der Autor:innen

AtezolizumabBevacizumabDurvalumabHepatocellular carcinomaImmunotherapyMatching-adjusted indirect comparisonReal-world evidenceRestricted mean survival timeSTRIDE regimenSurvival analysisTime-varying hazardTremelimumab

Substanzen

Antibodies, Monoclonal, HumanizedBevacizumabatezolizumabAntibodies, Monoclonaltremelimumabdurvalumab

Autor:innen und Institutionen

  • Department of Oncology, IRCCS San Raffaele Hospital, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy. Electronic address: casadeigardini.andrea@hsr.it.
  • Medical Data Analytics Centre, Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong Special Adminis…
  • Department of Surgery, Oncology and Gastroenterology, University of Padova, Padua, Italy.
  • Department of Oncology, IRCCS San Raffaele Hospital, Milan, Italy; "Vita-Salute" San Raffaele University, Milan, Italy.
  • Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
  • Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-8638, Japan.

Zitieren

APA

Casadei-Gardini, A., Yip, T. C., Vitale, A., Rossari, F., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H. Y., Presa, J., Masi, G., Yoo, C., Lonardi, S., Piscaglia, F., Kumada, T., Scartozzi, M., Tamburini, E., …, & Rimini, M. (2026). Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116750

Vancouver

Casadei-Gardini A, Yip TC, Vitale A, Rossari F, Tada T, Suda G, et al. Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116750

BibTeX
@article{CasadeiGardini2026,
  author = {Casadei-Gardini, Andrea and Yip, Terry Cheuk-Fung and Vitale, Alessandro and Rossari, Federico and Tada, Toshifumi and Suda, Goki and Shimose, Shigeo and Kudo, Masatoshi and Cheon, Jaekyung and Finkelmeier, Fabian and Lim, Ho Yeong and Presa, José and Masi, Gianluca and Yoo, Changhoon and Lonardi, Sara and Piscaglia, Fabio and Kumada, Takashi and Scartozzi, Mario and Tamburini, Emiliano and Foschi, Francesco Giuseppe and Camera, Silvia and Persano, Mara and Pia D'Agata, Alessandra and Ferrara, Michele and Passeri, Laura and Rimassa, Lorenza and Rimini, Margherita},
  title = {Early and late survival dynamics of immunotherapy combinations in advanced HCC: Anchored indirect comparison of atezolizumab plus bevacizumab versus durvalumab + tremelimumab},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116750}
}
Kostenlos starten →